10975 N. Torrey Pines Road
71 articles with Epic Sciences
Epic Sciences, Inc. announced that it has named Chockalingam "Palani" Palaniappan as its new chief technology officer to help the company advance its Functional Cell Profiling technology to drive global expansion.
Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019
Epic Sciences, Inc. announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois.
Epic Sciences, Inc. announced the launch of a new brand identity, redesigned logo, tagline and website.
4/26/2019Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
Companies across Europe and Asia provide information about deal, clinical trials and more, with news from Synaptive Medical, Epic, Inventiva, Velabs, and more.
Enables Expanded Access to the Company's Portfolio of Tests
Epic Sciences, Inc. (Epic) announced the appointment of Richard J. Wenstrup, M.D. as chief medical officer.
Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial
Epic Sciences, Inc. and its research partners today report the use of the company's new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC).
3/29/2019Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.
Epic Sciences, Inc. announced that Lloyd Sanders has joined the company as president and chief executive officer.
Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer
Epic Sciences, Inc. announced today that new data will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2019, in Atlanta, Georgia, March 29 to April 4, 2019.
Epic Sciences Announces Completion of New York State Licensure to Provide the Oncotype DX AR-V7 Nucleus Detect Test for Patients with Metastatic Castration-Resistant Prostate Cancer in New York State
Epic Sciences, Inc. announced that the New York State Department of Health has completed licensure to provide the Oncotype DX® AR-V7 Nucleus Detect™ test for patients with metastatic castration-resistant prostate cancer.
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences' Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
PROPHECY validation trial published in Journal of Clinical Oncology
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019.
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 - 8 in San Antonio, TX.
Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer
Epic Sciences ("Epic"), is collaborating with four major breast cancer centers on a clinical trial to determine if Epic's blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer.
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage
Blue Ox Healthcare Partners, LLC (“Blue Ox” or the “Firm”), an investment firm focused on providing growth capital to healthcare companies in the middle market, today announced that it led a $52 million Series E investment in Epic Sciences, Inc.
Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation
Data demonstrated the company's "No Cell Left Behind" detection platform's capability to analyze potential markers of response to immuno-oncology agents.
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized